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Objective  To compare the effectiveness of extracorporeal shock wave therapy (ESWT) and trigger point injection 
(TPI) for the treatment of myofascial pain syndrome in the quadratus lumborum.
Methods  In a retrospective study at our institute, 30 patients with myofascial pain syndrome in the quadratus 
lumborum were assigned to ESWT or TPI groups. We assessed ESWT and TPI treatment according to their affects 
on pain relief and disability improvement. The outcome measures for the pain assessment were a visual analogue 
scale score and pain pressure threshold. The outcome measures for the disability assessment were Oswestry 
Disability Index, Roles and Maudsley, and Quebec Back Pain Disability Scale scores.
Results  Both groups demonstrated statistically significant improvements in pain and disability measures after 
treatment. However, in comparing the treatments, we found ESWT to be more effective than TPI for pain relief. 
There were no statistically significant differences between the groups with respect to disability.
Conclusion  Compared to TPI, ESWT showed superior results for pain relief. Thus, we consider ESWT as an 
effective treatment for myofascial pain syndrome in the quadratus lumborum.
Keywords  Extracorporeal shock wave therapy, Myofascial pain syndromes, Trigger point injection, Quadratus 
lumborum 
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INTRODUCTION
Myofascial pain syndrome (MPS) of the spinal stabilizer 
muscles is one of the most frequent causes of chronic low 
back pain. However, MPS is often overlooked. Among the 
spinal stabilizer muscles, the quadratus lumborum (QL) 
is frequently a trigger point and location of referred low 
back pain [1]. Overuse and strain of the QL is one of the 
major causes of chronic pain in the lower back. 
MPS is characterized by symptoms that include local-
ized muscular tenderness, myofascial trigger points, 
a palpable intramuscular taut band, and a muscular 
twitching response [2]. MPS is a common cause of pain 
and dysfunction in the musculoskeletal system and ac-
counts for 20% to 95% of cases with musculoskeletal pain 
presenting at outpatient clinics and pain management 
centers [3]. The primary goal of managing MPS is to 
break the vicious cycle of pain through the elimination 
of trigger points [4]. There are various treatments for the 
elimination of myofascial trigger points, including trigger 
point injection (TPI) [5], ischemic compression, stretch-
ing, massage, and treatment modalities, including ultra-
sound and transcu taneous electrical nerve stimulation. 
A variety of treatments exist, but the most effective treat-
ment for MPS is still under debate.
Recently, extracorporeal shock wave therapy (ESWT) 
has advanced as an alternative treatment for MPS in 
patients with symptoms recalcitrant to traditional con-
servative treatment [6]. ESWT is defined as a sequence of 
single sonic pulses characterized by high peak pressure – 
100 MP, a fast onset of pressure (<10 ns), and short dura-
tion (10 ms). ESWT is conveyed by an appropriate genera-
tor to a specific target area with an energy density in the 
range of 0.003–0.890 mJ/mm2 [7]. The transduction of an 
ESWT acoustic shock wave signal into a biological signal 
results in cell proliferation and/or differentiation via a 
mechano-transduction process [8]. Advantages of ESWT 
include its non-invasiveness and minimal side effects. As 
such, research on ESWT has recently increased to explore 
its effectiveness, particularly for MPS in the upper trape-
zius [9]. Thus far, research ESWT’s effectiveness is limited 
as to other areas, including the QL. 
Therefore, the aim of this study was to evaluate the 
clinical efficacy of ESWT for MPS in the QL. Our evalua-
tion compared pain and disability indices between two 
groups of subjects: patients who treated with ESWT, and 
patients who treated with TPI. 
MATERIALS AND METHODS
Subjects
We obtained approval for this study from the ethics 
committee of Gangnam Severance Hospital. This retro-
spective study enrolled 30 patients who were hospital-
ized at our institute between April 2015 and June 2016. 
Patients had a single diagnosis of MPS in the QL for lower 
back pain that persisted for more than 3 months. We 
conducted detailed medical examinations, administered 
by interviews and physical examinations. Based on the 
diagnosis standard presented by Simons and Mense [10] 
and Vecchiet et al. [11], we diagnosed the subjects as hav-
ing MPS when they exhibited the following: pain at local 
sites of QL muscle; short taut bands formed; pain when 
the QL muscles were pressed; and pain trigger points, 
causing referred pain at relatively accurate spots around 
the QL muscles. We detected trigger points by using both 
thumbs while subjects lay in prone postion. 
To improve the valid inclusion criteria, study subjects 
were included when all described conditions were satis-
fied. Differential diagnosis was also evaluated by other 
examinations. These examinations included L-spine 
MRI, EMG, and simple X-ray for differentiating other pa-
thologies, such as spinal stenosis, spinal tumor, herniated 
nucleus pulposus, spondylolisthesis, spinal instability, 
and spinal anomaly under medical imaging inspection, 
and lumbosacral, radiculopathy, and myelopathy. 
We excluded subjects with the following: a prior history 
of receiving ESWT or lumbar spine surgery; neurological 
deficits involving the lower extremities; cardiovascular 
disease; inflammatory arthritis; local infection; malig-
nancy; cardiac arrhythmia; cardiac pacemaker; and 
pregnancy. 
For patients diagnosed with MPS, we confirmed their 
sex, age, time of occurrence of the lesion, area of the 
lesion, concomitant diseases, and presence of any pre-
ceding injury. We then allowed the patients to select 
between ESWT or TPI as their treatment method after 
we explained our study’s purposes. Of the 30 patients, 15 
received a TPI and 15 received ESWT. All patients under-
went conservative treatment that included analgesics, 
rest, and therapeutic exercises. 
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Primary outcome measure: pain evaluation 
The primary outcome measure is an assessment of pain 
using two methods: (1) a visual analogue scale (VAS) and 
(2) measurement of the pressure pain threshold (PPT). 
We used the VAS to estimate pain intensity on a scale of 
0 to 10. A score of 10 indicated maximal pain and 0 indi-
cated no pain. 
We measured PPT as patients lay in a prone position. 
We used ultrasonography to mark the location for the 
measurement at the mid-point of the QL muscle belly. To 
do this, we vertically applied a digital algometer (OE-220, 
ITO, Tokyo, Japan) to the surface of the tender point, and 
the subjects were instructed to say “stop” when they felt 
pain. That moment was measured in units of kg/cm2. We 
repeated this procedure three times at 30-second inter-
vals, and recorded the av erage value as the PPT. Using a 
digital algometer, we evaluated the criterion level of pain 
or discomfortness at VAS 5 level, and confirmed the PPT 
of a tender point when there was a difference of more 
than 2 kg/cm2, compared to a non-tender point. PPT was 
recoded in the case of both described conditions. [12]
Secondary outcome measure: disability evaluation 
The secondary outcome measure assesses disabil-
ity using three methods: the Oswestry Disability Index 
(ODI); the Roles and Maudsley (RM) score; and the Que-
bec Back Pain Disability Scale (QBS). The ODI is a self-
administered measuring tool, conducted by checking 
the subject’s level of pain during nine different activities: 
personal hygiene, lifting objects, walking, sitting, stand-
ing, sleeping, social activity, traveling, and ambulation. 
Higher scores indicate a greater dysfunctional status re-
sulting from the lower back pain [13]. The RM score is a 
functional assessment of pain during daily life activities, 
scored as excellent, good, fair, or poor [14]. The QBS is a 
condition-specific questionnaire designed to measure 
the level of functional disability for patients with lower 
back pain. The QBS measures for 20 daily activities under 
six overall categories.
Treatment
To identify the QL muscle, we used the Accuvix V10 
(Samsung Medison, Seoul, Korea) with a linear transduc-
er at frequencies of 5–13 MHz. Patients were in the prone 
position during the examination. 
For patients who opted for ESWT, we used a Dornier 
AR2 with smart focus technology (MedTech, Munchen, 
Germany). We applied the device at the tender point of 
the QL muscle belly, with 2,000 shock waves applied at 
each session at an intensity of 0.085–0.148 mJ/mm2. We 
repeated this procedure a total of three times, at 3-day 
intervals. 
For TPI patients, we similarly administered the TPI 
three times at the tender point of the QL at 3-day inter-
vals. For this procedure, we used a digital algometer for 
localizing the tender point by measuring pain threshold. 
We conducted ESWT and TPI in a ultrasound-guided 
fashion to diminish bias resulting from technical errors. 
We conducted a gross observation of the ultrasound to 
check for twitch response.
Assessment
We assessed clinical outcomes three times: before the 
initial treatment (pre-treatment assessment), immediate-
ly after the third treatment (post-treatment assessment), 
and 1 month after treatment at the outpatient clinic (fol-
low-up assessment). To compare the treatment efficacies, 
we recorded differences seen in the post-treatment and 
follow-up assessment, compared to the pre-treatment 
assessment (Table 1). We monitored adverse effects both 
before and after the application of the ESWT or TPI. 
Statistical analyses
We used general linear modeling as our main analytic 
approach. A univariate repeated-measures analysis of 
variance (ANOVA) was conducted for each of the three 
assessment times for each outcome measure (VAS, PPT, 
ODI, RM score, and QBS) and treatment group (ESWT 
group vs. TPI group). This approach permitted the mod-
eling of both individual and sets of outcome measures, 
as a function of treatment effects (between subjects) and 
time of assessment (within subjects). Hence, the interac-
tion effect of treatment × time was of greatest interest. We 
also applied an independent t-test to compare the differ-
ences between treatment groups. 
All tests of statistical significance were interpreted with 
a criterion of p<0.05. We performed our statistical analy-
ses using SPSS release 12.0.1 for Windows (SPSS Inc., 
Chicago, IL, USA).
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RESULTS
The study included 30 patients (17 men and 13 wom-
en). Of the 15 subjects in the ESWT group, 8 were men 
and seven were women. In the TPI group, 9 were men 
and 6 were women. We observed no statistical differ-
ences between the two groups in terms of age, sex, body 
mass index, dis ease duration, and pre-treatment clinical 
outcomes (Table 2). 
In comparing the scores measured pre-treatment, the 
Table 2. Demographic comparison between ESWT and TPI groups
ESWT TPI p-value
Age (yr) 55.46±15.09 53.13±19.62 0.359
Sex (male:female) 8:7 9:6 0.656
BMI (kg/m2) 23.30±3.35 24.40±2.48 0.157
Disease duration (wk) 21.2±13.7 21.8±15.6 0.334
Values are presented as mean±standard deviation or number.
ESWT, extracorporeal shock wave therapy; TPI, trigger point injection; BMI, body mass index.
The chi-square test was used for the comparison of sex between two groups and Student t-test for age, BMI, and dis-
ease duration.
Table 1. The change of clinical outcomes of ESWT and TPI groups 
TPI group
(n=15)
p-value
ESWT group
(n=15)
p-value
VAS 
   Pre-treatment 6.64±1.08 7.33±0.82
   Post-treatment 3.71±0.73* 2.53±1.06*
   1 month follow-up 3.86±0.95* <0.01 2.13±0.92* <0.01
PPT 
   Pre-treatment 3.56±1.08 3.42±0.71
   Post-treatment 3.93±0.95 * 4.76±0.56*
   1 month follow-up 3.89±0.90 * 0.034 4.95±0.64* 0.025
ODI 
   Pre-treatment 31.71±8.97 26.47±7.40
   Post-treatment 20.79±10.37 * 15.67±9.43*
   1 month follow-up 20.64±10.28 * <0.01 15.53±9.50* <0.01
RM score 
   Pre-treatment 17.29±5.00 16.20±4.28
   Post-treatment 11.07±5.41* 9.67±4.61*
   1 month follow-up 12.71±4.36* <0.01 9.20±4.18* <0.01
QBS 
   Pre-treatment 53.57±16.44 48.13±19.18
   Post-treatment 34.43±19.10* 24.40±12.30*
   1 month follow-up 33.86±17.82* <0.01 23.30±10.22* <0.01
Values are presented as mean±standard deviation. 
ESWT, extracorporeal shock wave therapy; TPI, trigger point injection; VAS, visual analogue scale; PPT, pain pressure 
threshold; ODI, Oswestry Disability Index; RM score, Roles and Maudsley score; QBS, Quebec Back Pain Disability 
Scale.
Each p-value was calculated using F-ratio by repeated measured ANOVA for the pre-treatment, post-treatment, and 1 
month follow-up in a group. Hereby, * represents insignificance for post-hoc test result between post-treatment and 1 
month follow-up.
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clinical outcome assessment scores taken post-treatment 
and at the 1-month follow-up exam showed statistically 
significant differences in both groups, with decreases in 
the VAS, ODI, RM, and QBS scores, and an increase in the 
PPT (Table 1). Moreover, the clinical outcome scores be-
tween post-treatment and 1-month follow-up showed no 
significant statistical difference in each study group (Table 
1). These results suggest that both ESWT and TPI are use-
ful treatments to improve pain and relieve disability in 
MPS patients with lower back pain. 
We found no statistically significant difference (p>0.05) 
between VAS and PPT in pre-treatment by an indepen-
dent t-test. However, we found significant differences 
between pre-treatment and post-treatment and pre-
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Fig. 1. Comparison of primary and secondary outcome 
measure scores in the ESWT and TPI groups. The squares 
and solid lines show results for the ESWT group, while 
the rounds and dotted lines represent results for the TPI 
group. ESWT, extracorporeal shock wave therapy; TPI, 
trigger point injection; VAS, visual analogue scale; PPT, 
pain pressure threshold; ODI, Oswestry Disability Index; 
RM score, Roles and Maudsley Score; QBS, Quebec Back 
Pain Disability Scale. Significant differences a)between 
pre-treatment and post-treatment and b)between pre-
treatment and the 1 month follow-up.
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treatment and the 1-month follow-up (p<0.05) (Fig. 1A, 
1B). There was a steeper difference in pain reduction in 
ESWT, compared to TPI.
However, there were no statistically significant differ-
ences between ESWT and TPI in the secondary disability 
indexes of ODI, RM score, and QBS when comparing im-
mediate post-treatment and 1 month after (p>0.05) (Fig. 
1C–1E). 
There were no serious adverse events, such as intoler-
able pain or subcutaneous infection, after treatment in 
either group. 
DISCUSSION
Our results showed that all three sessions of ESWT and 
TPI significantly reduced pain and improved the quality 
of life of patients with MPS in the QL, with no observable 
adverse effects. The comparison between the treatment 
groups showed there was a significantly greater pain re-
duction in the ESWT group, but no significant difference 
in the disability evaluation parameters. These findings 
suggest that ESWT is more effective than TPI for treating 
pain in patients with MPS in QL. 
The mechanism by which ESWT reduces MPS remains 
uncertain. MPS is a state in which stimulation of a trigger 
point in a muscle can result in referred pain. It is accom-
panied by deep pain that occurs in a fascia area connect-
ing to various muscle groups and bone. It is therefore 
important to eliminate the trigger point. Many research-
ers have sought to understand the effect of the charge 
applied in ESWT on the elimination of this trigger point. 
For example, it has been reported that applying ESWT to 
the lesion stimulates an increase in blood flow and the 
reformation of blood vessels [15]. In turn, this application 
stimulates a curative process in the muscle, tendon, and 
surrounding tissues/bones, leading to reactivation. A fur-
ther explanation may be that when the A delta receptor, 
which exhibits rapid neuro-stimulator transmission, is 
stimulated, this suppresses C fiber stimulation. The C fi-
ber stimulation has a slow neuro-stimulator transmission 
and is long lasting, and its suppression thereby blocks 
nerve conduction [16]. 
Our results differed from studies evaluating the use of 
ESWT for MPS in the upper trapezius muscle. Those stud-
ies showed no significant difference, whereas we found a 
significantly greater reduction in pain in the ESWT group 
compared to the TPI group. The different results may be 
due to the different locations of the QL and upper tra-
pezius muscles. The QL is more deeply located than the 
upper trapezius. Thus, we had a limitation in targeting 
TPI at the exact depth, although we applied ultrasound 
to increase the preciseness of the procedure. In addi-
tion, a previous study used a lower energy of 0.056 mJ/
mm2 applied at 1,000 impulses to the taut band, whereas 
our study used a higher energy of 0.085–0.148 mJ/mm2 
at 2,000 impulses. As ESWT has a dose-dependent effect 
[17], the use of different intensities and impulses may 
have influenced the treatment results. Finally, TPI is not 
always capable of thoroughouly addressing diffusely-
located multiple taut bands. In such cases, ESWT is an 
appropriate treatment option, with broader coverage and 
without post-injection soreness. 
Similar to the previous studies, we found no significant 
differences when comparing the disability evaluation. 
This may be due to the relatively short follow-up period. 
Any further study may need to include a longer follow-
up period. Additionally, disability may result from fac-
tors other than pain itself. It is also difficult to completely 
control the subjects’ daily activities. 
Based on our results, we can recommend ESWT as an 
effective treatment. It has many advantages, including 
non-invasiveness, less pain and complications compared 
to TPI, scarless cosmetic advantages, and no potential 
risks for infection or allergic reactions [18]. 
This study has three main limitations. First, this study 
was a retrospective study not a randomized controlled 
study. Therefore, subjects’ preferences towards treat-
ment method may have cause biased results. A future 
randomized control study should be attempted. Second, 
our sample size was relatively small with a short-term 
follow-up period. To increase compliance with ESWT, 
we limited our study subjects only to inpatients, and it 
was difficult to complete long-term follow-up after the 1 
month of post-treatment from the hospital. Because we 
only examined the immediate outcomes, we do not have 
the data to establish long-term effects. Third, this study 
lacks a placebo control group. However, we considered it 
unethical to withhold treatment from patients with pain 
and disability during the study period. 
In conclusion, ESWT for MPS in the QL resulted in a 
significantly greater reduction in pain compared to TPI, 
demonstrating the possibility of ESWT being an effective, 
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non-invasive treatment for patients with MPS in the QL. 
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